These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 38711496)
1. The impact of regulatory T cells on the graft-versus-leukemia effect. Pacini CP; Soares MVD; Lacerda JF Front Immunol; 2024; 15():1339318. PubMed ID: 38711496 [TBL] [Abstract][Full Text] [Related]
2. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. Bertaina A; Roncarolo MG Front Immunol; 2019; 10():1342. PubMed ID: 31354695 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
4. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
5. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489 [TBL] [Abstract][Full Text] [Related]
6. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B Front Immunol; 2020; 11():181. PubMed ID: 32117306 [TBL] [Abstract][Full Text] [Related]
8. Prevention of GVHD without losing GVL effect: windows of opportunity. Zhang P; Chen BJ; Chao NJ Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200 [TBL] [Abstract][Full Text] [Related]
9. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation]. Chang YJ; Huang XJ Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632 [TBL] [Abstract][Full Text] [Related]
10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173 [TBL] [Abstract][Full Text] [Related]
11. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
12. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705 [TBL] [Abstract][Full Text] [Related]
13. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Yao Y; Wang L; Zhou J; Zhang X J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349 [TBL] [Abstract][Full Text] [Related]
14. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M Front Immunol; 2020; 11():593863. PubMed ID: 33324410 [TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
16. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
17. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation. Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193 [TBL] [Abstract][Full Text] [Related]
18. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D Front Immunol; 2022; 13():907673. PubMed ID: 35677056 [TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic. Gu G; Yang JZ; Zhang JQ; Sun LX Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390 [TBL] [Abstract][Full Text] [Related]
20. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA Front Immunol; 2019; 10():295. PubMed ID: 30891031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]